Clinical trial
Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in…
NCT00308061 · U.S. Army Medical Research and Development Command, U.S. Fed · Completed
Key facts
| NCT number | NCT00308061 |
|---|---|
| Title | Safety Study of Candidate Malaria Vaccine FMP1/AS02A in Healthy Adults in Bandiagara, Mali |
| Official title | Double Blind Randomized Controlled Phase I Trial to Evaluate the Safety and Immunogenicity of WRAIR's MSP1 Candidate Malaria Vaccine (FMP1) Adjuvant in GSK Bio's AS02A vs. Rabies Vaccine in Semi-immune Adults in Bandiagara, Mali. |
| Lead sponsor | U.S. Army Medical Research and Development Command, U.S. Fed |
| Collaborators | National Institute of Allergy and Infectious Diseases (NIAID) NIH Walter Reed Army Institute of Research (WRAIR) U.S. Fed GlaxoSmithKline Industry United States Agency for International Development… |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Malaria |
| Intervention type | Biological |
| Interventions | FMP1/AS02A, Imovax Rabies Vaccine |
| Enrollment | 40 |
| Start date | Jul 1, 2003 |
| Primary completion | Sep 1, 2004 |
| Completion | Jul 1, 2005 |
| First posted | Mar 28, 2006 |
| Last update posted | Jul 31, 2017 |
| Countries | Mali |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: